ABBVIE (ABBVIE) News
Track canonical SquawkNews coverage tagged to ABBVIE, ABBVIE. This hub brings together deduplicated headlines about market instrument, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 3 indexed stories across 3 publication days and is ordered by the same first-publication timeline used by LiveCast.
M
AbbVie reports positive Phase 3 atogepant results in menstrual migraine
Atogepant met the primary and all eight ranked secondary endpoints in the Phase 3 Luna study, according to the report.
EQUITY | Sep 10, 2026, 01:03 PM UTC
L
AbbVie Q2 2026 Earnings
Adj EPS $3.65 (est $3.61) - Net Rev. $16.99B (est $16.77B) - Skyrizi Rev $5.51B (est $5.43B) - RINVOQ Rev. $2.53B (est $2.48B) - Humira Rev $756M (est $734.1M) - Imbruvica $532M (est $563.2M) - Sees FY Adj EPS $13.87 To
EARNINGS | Jul 31, 2026, 11:53 AM UTC
L
Abbvie Q2 2026 Earnings
Abbvie Q2 2026 Earnings
EARNINGS | Jul 30, 2026, 04:53 PM UTC